BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11603386)

  • 1. Surfactant protein D (SP-D) and systemic scleroderma (SSc).
    Maeda M; Ichiki Y; Aoyama Y; Kitajima Y
    J Dermatol; 2001 Sep; 28(9):467-74. PubMed ID: 11603386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
    Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
    Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.
    Bentow C; Swart A; Wu J; Seaman A; Manfredi M; Infantino M; Benucci M; Lakos G; Mahler M
    Clin Chim Acta; 2013 Sep; 424():141-7. PubMed ID: 23727029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.
    Yin L; Ge Y; Yang H; Peng Q; Lu X; Zhang Y; Wang G
    Clin Rheumatol; 2016 Nov; 35(11):2715-2721. PubMed ID: 27502600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.
    Greene KE; King TE; Kuroki Y; Bucher-Bartelson B; Hunninghake GW; Newman LS; Nagae H; Mason RJ
    Eur Respir J; 2002 Mar; 19(3):439-46. PubMed ID: 11936520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
    Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
    Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of vascular endothelial growth factor in collagen diseases.
    Kikuchi K; Kubo M; Kadono T; Yazawa N; IHN H; Tamaki K
    Br J Dermatol; 1998 Dec; 139(6):1049-51. PubMed ID: 9990370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
    Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
    Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Hamaguchi Y; Fujimoto M; Takehara K; Sato S
    Clin Exp Rheumatol; 2003; 21(4):429-36. PubMed ID: 12942693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
    Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
    J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome.
    Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
    Arthritis Res Ther; 2004; 6(2):73-4. PubMed ID: 15059267
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
    J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-C1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis.
    Liaskos C; Rentouli S; Simopoulou T; Gkoutzourelas A; Norman GL; Brotis A; Alexiou I; Katsiari C; Bogdanos DP; Sakkas LI
    Br J Dermatol; 2019 Jul; 181(1):138-146. PubMed ID: 30875084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.